A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- Registration Number
- NCT02629159
- Lead Sponsor
- AbbVie
- Brief Summary
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
- Detailed Description
This study consists of a 48-week double-blind treatment period (Period 1) and a long-term extension period (Period 2).
Period 1 is a 48-week randomized, double-blind, parallel-group, placebo-controlled and active comparator-controlled period designed to compare the safety and efficacy of upadacitinib versus placebo, and versus adalimumab. Participants will be randomized in a 2:2:1 ratio to one of three treatment groups:
* Placebo (up to Week 26)
* Upadacitinib 15 mg once daily (QD)
* Adalimumab 40 mg every other week (eow)
Participants randomized to placebo who do not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline will be switched to blinded upadacitinib treatment. At Week 26, all participants still receiving placebo will be switched to blinded upadacitinib treatment regardless of clinical response.
Participants randomized to adalimumab who do not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline will be switched to blinded upadacitinib. Participants still receiving adalimumab at Week 26 who do not achieve low disease activity (LDA) according to Clinical Disease Activity Index (CDAI; LDA is defined as CDAI ≤ 10) will be switched to blinded upadacitinib treatment to Week 48.
Participants randomized to upadacitinib who do not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline will be switched to blinded adalimumab; participants still receiving upadacitinib at Week 26 who do not achieve LDA (CDAI ≤ 10) will be switched to blinded adalimumab treatment to Week 48.
Participants who complete the Week 48 visit (end of Period 1) will enter the long-term extension phase of the study (Period 2), for up to 5 years. Participants will continue study treatment as assigned at the end of Period 1. Starting at the Week 48 and thereafter, at least 20% improvement in both TJC and SJC compared to Baseline is required to remain on study drug. Anyone who does not fulfill this criterion at 2 consecutive visits (starting at Week 48) will be discontinued.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1629
- Adult male or female, at least 18 years old.
- Diagnosis of RA for greater than or equal to 3 months.
- Subjects must have been on oral or parenteral methotrexate (MTX) therapy greater than or equal to 3 months and on a stable prescription of greater than or equal to 15 to 25 mg/week (or greater than or equal to 10 mg/week in subjects intolerant of MTX at doses greater than or equal to 12.5 mg/week) for at least 4 weeks prior to the first dose of study drug. In addition all subjects should take a dietary supplement of folic acid or folinic acid throughout the study participation.
- Meets the following minimum disease activity criteria: greater than or equal to 6 swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
- At least one of the following at Screening: greater than or equal to 3 bone erosions on x-ray OR greater than or equal to 1 bone erosion and a positive rheumatoid factor OR greater than or equal to 1 bone erosion and a positive anti-cyclic citrullinated peptide autoantibodies.
- Subjects with prior exposure to only one biological disease-modifying anti-rheumatic drugs (bDMARD) (except adalimumab) may be enrolled (up to 20% of total study population) if they have documented evidence of intolerance to the bDMARD or limited exposure (less than 3 months), but required washout periods need to be satisfied.
- Except for MTX, subject must have discontinued all conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
- Subjects who have been exposed to adalimumab or who are considered inadequate responders to bDMARD therapy as determined by the Investigator.
- History of inflammatory joint disease other than RA. History of secondary Sjogren's Syndrome is permitted.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo followed by ABT-494 Placebo for Upadacitinib Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1). Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2. Adalimumab Placebo for Upadacitinib Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index \[CDAI\] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48. Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2. Adalimumab Adalimumab Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index \[CDAI\] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48. Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2. Placebo followed by ABT-494 Placebo for Adalimumab Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1). Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2. Upadacitinib Placebo for Adalimumab Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48. Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2. Placebo followed by ABT-494 Upadacitinib Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1). Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2. Adalimumab Upadacitinib Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index \[CDAI\] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48. Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2. Upadacitinib Upadacitinib Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48. Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2. Upadacitinib Adalimumab Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48. Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2.
- Primary Outcome Measures
Name Time Method Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 Baseline and Week 12 The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
1. ≥ 20% improvement in 68-tender joint count;
2. ≥ 20% improvement in 66-swollen joint count; and
3. ≥ 20% improvement in at least 3 of the 5 following parameters:
* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 Week 12 The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was clinical remission, based on a Disease Activity Score 28 (DAS28)-CRP score of \< 2.6 at Week 12.
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28 score less than 2.6 indicates clinical remission.
- Secondary Outcome Measures
Name Time Method Change From Baseline in DAS28 (CRP) at Week 12 Baseline and Week 12 The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26 Baseline and Week 26 The mTSS measures the level of joint damage from radiographs of the hands and feet, assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score.
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
JSN was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).
The mTSS is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 448 (worst). A negative change from Baseline in mTSS indicates improvement in joint damage whereas a change from Baseline greater than 0 indicates progression.Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 Baseline and Week 12 The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 Baseline and Week 12 Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
1. ≥ 50% improvement in 68-tender joint count;
2. ≥ 50% improvement in 66-swollen joint count; and
3. ≥ 50% improvement in at least 3 of the 5 following parameters:
* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 Baseline and Week 12 The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Baseline and Week 12 The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 Week 12 The DAS28(CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.
A DAS28(CRP) score less than or equal to 3.2 indicates low disease activity.Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12 Week 12 Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.
CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.Change From Baseline in Duration of Morning Stiffness at Week 12 Baseline and Week 12 Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days. A negative change from Baseline indicates improvement.
Change From Baseline in Patient's Assessment of Pain at Week 12 Baseline and Week 12 Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100. A score of 0 indicates "no pain" and a score of 100 indicates "worst possible pain." A negative change from Baseline indicates improvement.
Percentage of Participants With No Radiographic Progression at Week 26 Baseline and Week 26 No radiographic progression is defined as a change from Baseline in mTSS ≤ 0. The mTSS measures the level of joint damage from radiographs of the hands and feet, which were assessed by 2 independent, blinded readers. mTSS is calculated as the sum of the total joint erosion score and total joint space narrowing (JSN) score and ranges from 0 (normal) to 448 (worst).
Joint erosion severity was assessed in 16 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 280 (worst).
Joint space narrowing (JSN) was assessed in 15 joints of each hand and wrist, and 6 joints of each foot, including subluxation, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 168 (worst).Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 Baseline and Week 12 Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
1. ≥ 70% improvement in 68-tender joint count;
2. ≥ 70% improvement in 66-swollen joint count; and
3. ≥ 70% improvement in at least 3 of the 5 following parameters:
* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).
Trial Locations
- Locations (370)
Precision Research Org, LLC /ID# 143092
🇺🇸Miami Lakes, Florida, United States
DM Clinical Research /ID# 151357
🇺🇸Tomball, Texas, United States
Arthritis Clinical Research Tr /ID# 144874
🇿🇦Cape Town, Western Cape, South Africa
Riesgo de Fractura S.A - CAYRE /ID# 142896
🇨🇴Bogota, Colombia
Arthritis and Rheumatology /ID# 155668
🇺🇸Atlanta, Georgia, United States
Great Lakes Clinical Trials /ID# 148357
🇺🇸Chicago, Illinois, United States
Pioneer Research Solutions, Inc. /ID# 145640
🇺🇸Houston, Texas, United States
Accurate Clinical Management /ID# 143089
🇺🇸San Antonio, Texas, United States
Arthritis & Osteo Ctr of S. TX /ID# 143103
🇺🇸San Antonio, Texas, United States
Cemic /Id# 148404
🇦🇷Buenos Aires, Argentina
MHAT Trimontsium /ID# 142874
🇧🇬Plovdiv, Bulgaria
Inst. Rheumatologic Strusberg /ID# 145601
🇦🇷Cordoba, Argentina
Consultora Integral de Salud S /ID# 144856
🇦🇷Cordoba, Argentina
Cliniques Universitaires Saint Luc /ID# 142858
🇧🇪Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
Cordis S.A. /Id# 152622
🇦🇷Salta, Argentina
Vital Medical Center Orvosi es /ID# 145950
🇭🇺Veszprém, Veszprem, Hungary
Centro Medico Privado/Reuma /ID# 142842
🇦🇷San Miguel de Tucuman, Argentina
RM Pharma Specialists, S.A de C.V /ID# 142994
🇲🇽Mexico City, Mexico
LKH-Univ. Klinikum Graz /ID# 142851
🇦🇹Graz, Austria
UZ Gent /ID# 142859
🇧🇪Gent, Oost-Vlaanderen, Belgium
University Clinical Centre of the Republic of Srpska /ID# 142862
🇧🇦Banja Luka, Republika Srpska, Bosnia and Herzegovina
Timaru Medical Specialists Ltd /ID# 143000
🇳🇿Timaru, New Zealand
UMHAT Pulmed OOD /ID# 142877
🇧🇬Plovdiv, Bulgaria
MHAT Kaspela /ID# 142873
🇧🇬Plovdiv, Bulgaria
UMHAT Sv. Ivan Rilski /ID# 142876
🇧🇬Sofia, Bulgaria
Paernu Hospital /ID# 142921
🇪🇪Pärnu, Estonia
Spitalul Clinic Sf. Maria /ID# 144869
🇷🇴Bucuresti, Romania
Ponce School of Medicine /ID# 151961
🇵🇷Ponce, Puerto Rico
Arthritis Assoc & Osteo Ctr /ID# 143122
🇺🇸Colorado Springs, Colorado, United States
Manitoba Clinic /ID# 161434
🇨🇦Winnipeg, Manitoba, Canada
AZ Arthritis & Rheuma Research /ID# 143131
🇺🇸Phoenix, Arizona, United States
Arizona Research Center, Inc. /ID# 144877
🇺🇸Phoenix, Arizona, United States
Achieve Clinical Research, LLC /ID# 143136
🇺🇸Birmingham, Alabama, United States
Clinical Research West FL /ID# 148358
🇺🇸Tampa, Florida, United States
AZ Arthritis & Rheum Research /ID# 156093
🇺🇸Sun City, Arizona, United States
Arthritis Research of Florida /ID# 143125
🇺🇸Palm Harbor, Florida, United States
The Center for Rheumatology & /ID# 151356
🇺🇸Wheaton, Maryland, United States
Kotha and Kotha /ID# 161046
🇺🇸La Mesa, California, United States
ZASA Clinical Research /ID# 143134
🇺🇸Boynton Beach, Florida, United States
St. Luke's Hospital /ID# 156750
🇺🇸Duluth, Minnesota, United States
Arthritis Rheumatic Back Disorder /ID# 143102
🇺🇸Voorhees, New Jersey, United States
Ocean Rheumatology, PA /ID# 143111
🇺🇸Toms River, New Jersey, United States
Arthritis and Osteo Assoc /ID# 143127
🇺🇸Las Cruces, New Mexico, United States
Innovative Clinical Research /ID# 145637
🇺🇸Greenville, South Carolina, United States
Diagnostic Group Integrated He /ID# 148356
🇺🇸Beaumont, Texas, United States
Doctor's Hosp at Renaissance /ID# 154616
🇺🇸Edinburg, Texas, United States
West Virginia Research Inst /ID# 153088
🇺🇸South Charleston, West Virginia, United States
Arthritis Care and Diagnostic /ID# 150677
🇺🇸Dallas, Texas, United States
Metroplex Clinical Research /ID# 145631
🇺🇸Dallas, Texas, United States
Rheumatology and Immunotherapy Center /ID# 145646
🇺🇸Franklin, Wisconsin, United States
Rheumatology Clinic of Houston /ID# 150921
🇺🇸Houston, Texas, United States
The Vancouver Clinic, INC. PS /ID# 143107
🇺🇸Vancouver, Washington, United States
Consultorio Reumatologic Pampa /ID# 144853
🇦🇷Buenos Aires, Argentina
Org Medica de Investigacion /ID# 144855
🇦🇷Buenos Aires, Argentina
Instituto CAICI /ID# 144854
🇦🇷Rosario, Santa FE, Argentina
Hc Ufmg /Id# 142868
🇧🇷Belo Horizonte, Minas Gerais, Brazil
Fundacion Sanatorio Guemes /ID# 148405
🇦🇷Buenos Aires, Argentina
Iari /Id# 151293
🇦🇷San Fernando, Argentina
Rhumaconsult SPRL /ID# 142860
🇧🇪Charleroi, Hainaut, Belgium
Ciads /Id# 142880
🇨🇦Winnipeg, Manitoba, Canada
Someal /Id# 144704
🇨🇱Providencia-santiago, Chile
Aprillus Asistencia e Investig /ID# 148406
🇦🇷Capital Federal, Buenos Aires, Argentina
Mautalen Salud e Investigacion /ID# 142843
🇦🇷Buenos Aires, Argentina
Centro Integral de Reumatologi /ID# 142845
🇦🇷San Miguel de Tucuman, Argentina
Centro de Enfermedades /ID# 153542
🇦🇷Santa Fe, Argentina
Royal Prince Alfred Hospital /ID# 144857
🇦🇺Camperdown, New South Wales, Australia
First City Clinical Hospital /ID# 158011
🇧🇾Minsk, Belarus
CHU de Liege /ID# 148401
🇧🇪Liège, Liege, Belgium
CHU Ambroise Pare /ID# 152953
🇧🇪Mons, Belgium
University Clinical Centre of the Republic of Srpska /ID# 142863
🇧🇦Banja Luka, Republika Srpska, Bosnia and Herzegovina
Hospital de Clinicas de Porto Alegre /ID# 142870
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
LMK Sevicos Medicos S/S /ID# 142869
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Corp de Beneficencia Osorno /ID# 147941
🇨🇱Osorno, Chile
Adachi Medicine Prof. Corp /ID# 154205
🇨🇦Hamilton, Ontario, Canada
Centro Medico de Reumatologia /ID# 148402
🇨🇱Temuco, Chile
Ctr Int de Reum del Caribe SAS /ID# 142894
🇨🇴Barranquilla, Colombia
Fund Inst de Reum F. Chalem /ID# 149847
🇨🇴Bogota DC, Colombia
Praxis Walter, Rendsburg /ID# 142932
🇩🇪Rendsburg, Schleswig-Holstein, Germany
CHU Strasbourg Hautepierre Hos /ID# 144708
🇫🇷Strasbourg, France
Hopital Pitie Salpetriere /ID# 145605
🇫🇷Paris, France
Rheumaforschungszentrum II /ID# 142930
🇩🇪Hamburg, Germany
Klinicki bolnicki centar Rijeka /ID# 160232
🇭🇷Rijeka, Primorsko-goranska Zupanija, Croatia
Revmatologie Bruntal, s.r.o /ID# 142903
🇨🇿Bruntál, Czechia
Revmatologicka a interni ambul /ID# 142907
🇨🇿Kladno, Czechia
Medical Center Kuna-Peric /ID# 142901
🇭🇷Zagreb, Croatia
East Tallinn Central Hospital /ID# 142923
🇪🇪Tallinn, Estonia
North Estonian Medical Centre /ID# 145454
🇪🇪Tallinn, Estonia
Hopital Universitaire Purpan /ID# 144707
🇫🇷Toulouse, Haute-Garonne, France
CTCenter MaVe, s.r.o. /ID# 142905
🇨🇿Olomouc, Olomoucky Kraj, Czechia
REVMACLINIC s.r.o. /ID# 142906
🇨🇿Brno, Czechia
Center of Clinical and Basic Research /ID# 142922
🇪🇪Tallinn, Harjumaa, Estonia
Rheumazentrum Ruhrgebiet /ID# 145620
🇩🇪Herne, Nordrhein-Westfalen, Germany
Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 142948
🇭🇺Debrecen, Hungary
St Vincent's University Hosp /ID# 142957
🇮🇪Dublin, Ireland
Bnai Zion Medical Center /ID# 151958
🇮🇱Haifa, Israel
The Lady Davis Carmel MC /ID# 142960
🇮🇱Haifa, Israel
Istituto Clinico Humanitas /ID# 147528
🇮🇹Rozzano, Milano, Italy
AOU Citta della Salute Scienza /ID# 150070
🇮🇹Turin, Piemonte, Italy
Azienda Ospedaliera Luigi Sacc /ID# 142966
🇮🇹Milan, Italy
Chungnam National University Hospital /ID# 142977
🇰🇷Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of
LTD M+M Centers /ID# 142984
🇱🇻Adazi, Latvia
Daugavpils Regional Hospital /ID# 142982
🇱🇻Daugavpils, Latvia
Karaganda State Medical Univ /ID# 153433
🇰🇿Karaganda, Kazakhstan
Semey State Medical University /ID# 152659
🇰🇿Semey, Kazakhstan
Regional Clinical Hospital /ID# 147168
🇰🇿Shymkent, Kazakhstan
Hanyang University Seoul Hospi /ID# 142979
🇰🇷Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of
D.Saulites-Kandevicas PP /ID# 142985
🇱🇻Liepaja, Latvia
Hosp Lithuanian Univ Health Sc /ID# 142986
🇱🇹Kovno, Kaunas, Lithuania
Clinic ORTO /ID# 142983
🇱🇻Riga, Latvia
Hospital Selayang /ID# 156756
🇲🇾Batu Caves, Malaysia
Hospital Umum Sarawak /ID# 142990
🇲🇾Kuching, Malaysia
Hospital Putrajaya /ID# 142989
🇲🇾Putrajaya, Malaysia
Hospital Tuanku Ja afar /ID# 142988
🇲🇾Seremban, Malaysia
Clinstile, S.A. de C.V. /ID# 144866
🇲🇽Cuauhtemoc, Ciudad De Mexico, Mexico
Centro Peninsular de Investiga /ID# 148159
🇲🇽Mérida, Mexico
Waikato Hospital /ID# 143002
🇳🇿Hamilton, Waikato, New Zealand
Porter Rheumatology Ltd /ID# 143001
🇳🇿Nelson, New Zealand
WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 145622
🇵🇱Wrocław, Dolnoslaskie, Poland
Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163294
🇵🇱Gdynia, Pomorskie, Poland
Solumed Sp. zoo Cent Medyczne /ID# 152783
🇵🇱Poznan, Poland
Instituto Portugues De Reumatologia /ID# 148316
🇵🇹Lisbon, Lisboa, Portugal
LLC Novaya Klinika /ID# 143019
🇷🇺Pyatigorsk, Stavropol Skiy Kray, Russian Federation
Jakaranda Hosp, Emmed Research /ID# 143046
🇿🇦Pretoria, Gauteng, South Africa
Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163293
🇵🇱Gdynia, Pomorskie, Poland
CCA Braga - Hospital de Braga /ID# 148317
🇵🇹Braga, Portugal
Hospital CUF Descobertas /ID# 160539
🇵🇹Lisbon, Portugal
Centro Hospitalar De Vila Nova /ID# 143010
🇵🇹Vila Nova De Gaia, Porto, Portugal
ClinicMed Badurski i wspolnicy SJ /ID# 163300
🇵🇱Bialystok, Poland
Rheuma Medicus /ID# 143007
🇵🇱Warsaw, Poland
Unidade Local De Saude Do Alto Minho /ID# 143009
🇵🇹Viana Do Castelo, Portugal
Spitalul Clinic Dr. I. Cantacuzino /ID# 143012
🇷🇴Bucharest, Bucuresti, Romania
Spitalul Clinic Sf. Maria /ID# 145966
🇷🇴Bucuresti, Romania
Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163295
🇵🇱Gdynia, Pomorskie, Poland
Silmedic Sp z o.o /ID# 152914
🇵🇱Katowice, Slaskie, Poland
Centro Hospitalar de Sao Joao, EPE /ID# 152871
🇵🇹Porto, Portugal
Institute for Rheumatology /ID# 143035
🇷🇸Belgrade, Beograd, Serbia
Reumatologická ambulancia Reum.hapi s.r.o. /ID# 147169
🇸🇰Nové Mesto Nad Váhom, Slovakia
Slovak research center Team Member, Thermium s.r.o. /ID# 147614
🇸🇰Pieštany, Slovakia
Winelands Medical Research Ctr /ID# 143048
🇿🇦Stellenbosch, Western Cape, South Africa
Clinical Center of Vojvodina /ID# 143033
🇷🇸Novi Sad, Vojvodina, Serbia
Complejo Hosp Santiago /ID# 153727
🇪🇸Santiago de Compostela, Spain
ALBAMED s.r.o. /ID# 143042
🇸🇰Zvolen, Slovakia
Taipei Veterans General Hosp /ID# 157940
🇨🇳Taipei City, Taiwan
Istanbul Fizik Tedavi Rehabilitasyon Egitim ve Arastırma Hastanesi /ID# 143063
🇹🇷Istanbul, Turkey
H. Un. Marques de Valdecilla /ID# 143050
🇪🇸Santander, Cantabria, Spain
Clinica Gaias /ID# 143052
🇪🇸Santiago de Compostela, Spain
Tiervlei Trial Centre /ID# 153085
🇿🇦Cape Town, Western Cape, South Africa
Greenacres Hospital /ID# 144710
🇿🇦Port Elizabeth, Eastern Cape, South Africa
Reumatologicka ambulancia, LER /ID# 143044
🇸🇰Topolcany, Slovakia
Comple Hosp Univ de A Coruna /ID# 143051
🇪🇸A Coruna, Spain
Hospital Universitario Reina S /ID# 153566
🇪🇸Cordoba, Spain
University of Pretoria /ID# 148353
🇿🇦Pretoria, Gauteng, South Africa
Kaohsiung Medical University /ID# 143059
🇨🇳Kaohsiung, Taiwan
Kaohsiung Chang Gung Memorial Hospital /ID# 143055
🇨🇳Kaohsiung, Taiwan
Queen Alexandra Hospital /ID# 143077
🇬🇧Portsmouth, United Kingdom
LLC Revmocentr /ID# 143067
🇺🇦Kiev, Kyiv, Ukraine
Far Eastern Memorial Hospital /ID# 143061
🇨🇳New Taipei City, Taiwan
Istanbul Universitesi Cerrahpa /ID# 156088
🇹🇷Cerrahpasa, Turkey
NSC-Strazhesko Ist Cardiology /ID# 152030
🇺🇦Kiev, Ukraine
Izmir Katip Celebi Ataturk Training & Research Hospital /ID# 143062
🇹🇷Izmir, Turkey
Lviv Municipal City Clinical /ID# 143068
🇺🇦Lviv, Ukraine
Zaporizhzhia Regional Clinical /ID# 143069
🇺🇦Zaporizhia, Ukraine
Lviv Regional Clinical Hospita /ID# 154450
🇺🇦Lviv, Lvivska Oblast, Ukraine
Odessa National Medical Univ /ID# 143072
🇺🇦Odesa, Ukraine
Osteoporosis Medical Center /ID# 153935
🇺🇸Beverly Hills, California, United States
T. Joseph Raoof, MD, Inc. /ID# 144884
🇺🇸Encino, California, United States
C.V. Mehta MD, Med Corporation /ID# 143116
🇺🇸Hemet, California, United States
TriWest Research Associates- La Mesa /ID# 143115
🇺🇸La Mesa, California, United States
Discovery MM Services, Inc /ID# 163504
🇺🇸Los Angeles, California, United States
Robin K. Dore MD, Inc /ID# 143090
🇺🇸Tustin, California, United States
Medvin Clinical Research /ID# 148362
🇺🇸Whittier, California, United States
St. Lawrence Health System /ID# 161619
🇺🇸Potsdam, New York, United States
EmergeOrtho, P.A. /ID# 143100
🇺🇸Durham, North Carolina, United States
Albuquerque Clinical Trials, Inc /ID# 143083
🇺🇸Albuquerque, New Mexico, United States
Joint & Muscle Research Instit /ID# 143119
🇺🇸Charlotte, North Carolina, United States
DJL Clinical Research, PLLC /ID# 143101
🇺🇸Charlotte, North Carolina, United States
Shanahan Rheuma & Immuno /ID# 145643
🇺🇸Raleigh, North Carolina, United States
Clinical Research Solutions, LLC /ID# 154619
🇺🇸Dayton, Ohio, United States
Altoona Ctr Clinical Res /ID# 143110
🇺🇸Duncansville, Pennsylvania, United States
Healthcare Research Consultant /ID# 143129
🇺🇸Tulsa, Oklahoma, United States
Clinical Research Ctr Reading /ID# 143133
🇺🇸Wyomissing, Pennsylvania, United States
MedResearch Inc. /ID# 154618
🇺🇸El Paso, Texas, United States
Accurate Clinical Management /ID# 145644
🇺🇸Houston, Texas, United States
Accurate Clinical Research /ID# 145645
🇺🇸Houston, Texas, United States
Discovery MM Services, Inc. /ID# 163184
🇺🇸Missouri City, Texas, United States
Arthritis Northwest, PLLC /ID# 143088
🇺🇸Spokane, Washington, United States
Revmatologicky ustav Praha /ID# 142904
🇨🇿Prague 2, Praha 2, Czechia
Revmatologická ambulance /ID# 145963
🇨🇿Prague 4, Praha 4, Czechia
Arthromed, s.r.o. /ID# 144706
🇨🇿Pardubice, Czechia
BayCare Medical Group, Inc. /ID# 143085
🇺🇸Tampa, Florida, United States
University of Arizona Cancer Center - North Campus /ID# 143114
🇺🇸Tucson, Arizona, United States
Valerius Med Grp & Res Ctr /ID# 143120
🇺🇸Los Alamitos, California, United States
Desert Medical Advances /ID# 143097
🇺🇸Palm Desert, California, United States
Sierra Rheumatology /ID# 155672
🇺🇸Roseville, California, United States
Rheumatology Ctr of San Diego /ID# 153747
🇺🇸Escondido, California, United States
Allergy and Rheum Med Clin /ID# 146083
🇺🇸La Jolla, California, United States
North Georgia Rheumatology Grp /ID# 147170
🇺🇸Lawrenceville, Georgia, United States
Atlantic Coast Research /ID# 148355
🇺🇸Toms River, New Jersey, United States
Cape Fear Arthritis Care /ID# 148361
🇺🇸Leland, North Carolina, United States
Arthritis Assoc of NW Ohio /ID# 143094
🇺🇸Toledo, Ohio, United States
Coastal Carolina Health Care /ID# 148359
🇺🇸New Bern, North Carolina, United States
Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 143091
🇺🇸Summerville, South Carolina, United States
Columbia Arthritis Center /ID# 153730
🇺🇸Columbia, South Carolina, United States
Austin Regional Clinic /ID# 143084
🇺🇸Austin, Texas, United States
Dr. Ramesh Gupta /ID# 143099
🇺🇸Memphis, Tennessee, United States
Houston Institute for Clin Res /ID# 144879
🇺🇸Houston, Texas, United States
Arthritis Consultants, P.A. /ID# 144880
🇺🇸Killeen, Texas, United States
Arthritis & Osteoporosis Assoc /ID# 147364
🇺🇸Lubbock, Texas, United States
P&I Clinical Research /ID# 161625
🇺🇸Lufkin, Texas, United States
Sun Research Institute /ID# 159539
🇺🇸San Antonio, Texas, United States
Discovery MM Services, Inc. /ID# 163183
🇺🇸Missouri City, Texas, United States
Discovery MM Services, Inc. /ID# 162578
🇺🇸Missouri City, Texas, United States
Arthritis Clinic of N. VA, P.C /ID# 143109
🇺🇸Arlington, Virginia, United States
Ctr for Arth and Rheum Disease /ID# 143113
🇺🇸Chesapeake, Virginia, United States
CIP - Centro Internacional de Pesquisa /ID# 142872
🇧🇷Goiânia, Goias, Brazil
CA Ctr for Clin Trials CCCT /ID# 157379
🇨🇦Thornhill, Ontario, Canada
St. Clare's Mercy Hospital /ID# 142879
🇨🇦St. John's, Newfoundland and Labrador, Canada
Groupe de Recherche en Maladies Osseuses /ID# 142878
🇨🇦Sainte-foy, Quebec, Canada
Quantum Research Stgo. /ID# 157933
🇨🇱Santiago, Chile
Quantum Research LTDA. /ID# 142893
🇨🇱Puerto Varas, Chile
Investigaciones Medicas SSMSO /ID# 151686
🇨🇱Santiago, Chile
Clinica DermaCross /ID# 142892
🇨🇱Santiago, Chile
Centro Inter Estud Clin CIEC /ID# 144777
🇨🇱Santiago, Chile
Cinvec /Id# 144705
🇨🇱Vina Del Mar, Chile
Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 142898
🇨🇴Bogota, Cundinamarca, Colombia
Medicity S.A.S. /ID# 144860
🇨🇴Bucaramanga, Colombia
Centro Integral de Reumatologi /ID# 142897
🇨🇴Medellín, Colombia
Clinical Hospital Dubrava /ID# 142900
🇭🇷Zagreb, Croatia
L.K.N. Arthrocentrum, s.r.o /ID# 145961
🇨🇿Hlučín, Moravskoslezsky Kraj, Czechia
Nuselská poliklinika, Revmatologie /ID# 144862
🇨🇿Prague 4, Praha 4, Czechia
Thomayerova nemocnice /ID# 145962
🇨🇿Prague 4, Praha 4, Czechia
Revmatologie MUDr. Klara Sirov /ID# 142908
🇨🇿Ostrava, Czechia
Aarhus University Hospital /ID# 158838
🇩🇰Aarhus N, Midtjylland, Denmark
Regionhospital Silkeborg /ID# 142914
🇩🇰Silkeborg, Denmark
MediTrials /ID# 151870
🇪🇪Tartu, Tartumaa, Estonia
CHU Bordeaux-Hopital Pellegrin /ID# 145618
🇫🇷Bordeaux, France
Med Versorgungszentrum AGILOME /ID# 154975
🇩🇪Chemnitz, Germany
LMU Klinikum der Universität München /ID# 142931
🇩🇪Munich, Germany
Markusovszky Egyetemi Oktatókórház /ID# 145621
🇭🇺Szombathely, Vas, Hungary
Kiskunhalasi Semmelweis Korhaz /ID# 151944
🇭🇺Kiskunhalas, Hungary
A.O.U.I. di Verona Policlinico /ID# 142963
🇮🇹Verona, Italy
JSC Nat Scientific Med Res Ctr /ID# 142971
🇰🇿Astana, Kazakhstan
Kyungpook National Univ Hosp /ID# 162073
🇰🇷Daegu, Daegu Gwang Yeogsi, Korea, Republic of
Daegu Catholic University Med /ID# 142973
🇰🇷Daegu, Korea, Republic of
Chonnam National University Hospital /ID# 142975
🇰🇷Gwangju, Jeonranamdo, Korea, Republic of
Seoul National University Hospital /ID# 142978
🇰🇷Seoul, Korea, Republic of
Riga East Clinical Univ Hosp /ID# 142981
🇱🇻Riga, Latvia
Hospital Raja Perempuan Zainab II /ID# 157862
🇲🇾Kota Bharu, Kelantan, Malaysia
Hosp. Univ. Dr. Jose E. Gonz /ID# 142992
🇲🇽Monterrey, Nuevo Leon, Mexico
Invest y Biomed de Chihuahua /ID# 142996
🇲🇽Chihuahua, Mexico
REUMED Sp.z o.o. Filia nr 1 /ID# 148189
🇵🇱Lublin, Lubelskie, Poland
NZOZ Nasz Lekarz /ID# 143004
🇵🇱Toruń, Kujawsko-pomorskie, Poland
Malopolskie Centrum Kliniczne /ID# 152782
🇵🇱Cracow, Malopolskie, Poland
Pratia MCM Krakow /ID# 143005
🇵🇱Krakow, Malopolskie, Poland
McBk Sc /Id# 143003
🇵🇱Grodzisk Mazowiecki, Mazowieckie, Poland
Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 151960
🇵🇱Warszawa, Mazowieckie, Poland
Centrum Medyczne AMED Warszawa Targowek /ID# 157621
🇵🇱Warszawa, Mazowieckie, Poland
Osteo-Medic spolka cywilna /ID# 143006
🇵🇱Białystok, Podlaskie, Poland
Ecomed SRL /ID# 144870
🇷🇴Oradea, Romania
Perm Clinical Center of FMBA /ID# 145627
🇷🇺Perm, Permskiy Kray, Russian Federation
Kazan State Medical University /ID# 144871
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
Tver Regional Clinical Hosp. /ID# 143026
🇷🇺Tver, Tverskaya Oblast, Russian Federation
City Clinical Hospital #5 /ID# 148318
🇷🇺Nizhnij Novgorod, Russian Federation
Сity Clinical Hospital #4 /ID# 143023
🇷🇺Ivanovo, Russian Federation
Ryazan State Medical Universit /ID# 143031
🇷🇺Ryazan, Russian Federation
II Dzhan Research Center /ID# 143027
🇷🇺St. Petersburg, Russian Federation
Institute for Rheumatology /ID# 143032
🇷🇸Belgrade, Beograd, Serbia
Republican clinical hospital n /ID# 145626
🇷🇺UFA, Russian Federation
Institute for Rheumatology /ID# 143036
🇷🇸Belgrade, Beograd, Serbia
Reumatologicka ambulancia /ID# 144873
🇸🇰Sabinov, Slovakia
MEDMAN s.r.o. /ID# 143045
🇸🇰Martin, Slovakia
TIMMED spol. s r.o. /ID# 144872
🇸🇰Stará Lubovna, Slovakia
Wits Clinical Research Site /ID# 148320
🇿🇦Johannesburg, Gauteng, South Africa
National Taiwan Univ Hosp /ID# 143056
🇨🇳Taipei City, Taipei, Taiwan
The Royal Free Hospital /ID# 143074
🇬🇧London, London, City Of, United Kingdom
Warrington + Halton Hosp NHS /ID# 143075
🇬🇧Warrington, United Kingdom
SunValley Arthritis Center, Lt /ID# 143123
🇺🇸Peoria, Arizona, United States
AZ Arthritis and Rheum Assoc /ID# 143130
🇺🇸Mesa, Arizona, United States
Lakes Research, LLC /ID# 145630
🇺🇸Miami, Florida, United States
AZ Arthritis and Rheum Researc /ID# 143080
🇺🇸Phoenix, Arizona, United States
Lovelace Scientific Resources /ID# 143106
🇺🇸Venice, Florida, United States
Elite Clinical Studies, LLC /ID# 144881
🇺🇸Phoenix, Arizona, United States
AZ Arthritis and Rheum Researc /ID# 143121
🇺🇸Phoenix, Arizona, United States
AARDS Research, Inc. /ID# 154190
🇺🇸Aventura, Florida, United States
Clinical Res of West FL, Inc. /ID# 143112
🇺🇸Clearwater, Florida, United States
North Mississippi Med Clinics /ID# 145636
🇺🇸Tupelo, Mississippi, United States
FL Med Ctr and Research, Inc. /ID# 143081
🇺🇸Miami, Florida, United States
Ctr Arthritis & Rheumatic Dise /ID# 143135
🇺🇸Miami, Florida, United States
Quality Clinical Research Inc. /ID# 156394
🇺🇸Omaha, Nebraska, United States
Arthritis Treatment Center /ID# 155260
🇺🇸Frederick, Maryland, United States
St. Anthony Comprehsve Res Ins /ID# 143095
🇺🇸Saint Petersburg, Florida, United States
Arthritis Associates, PLLC /ID# 155490
🇺🇸Kingsport, Tennessee, United States
SW FL Clin Res Ctr, Tampa, FL /ID# 143117
🇺🇸Tampa, Florida, United States
Shores Rheumatology, PC /ID# 162977
🇺🇸Saint Clair Shores, Michigan, United States
International Medical Research /ID# 143132
🇺🇸Daytona Beach, Florida, United States
Clinical Pharmacology Study Gr /ID# 143082
🇺🇸Worcester, Massachusetts, United States
Physician Res. Collaboration /ID# 143087
🇺🇸Lincoln, Nebraska, United States
Advanced Rheumatology, PC /ID# 143118
🇺🇸Lansing, Michigan, United States
Advanced Clin Res of Orlando /ID# 154617
🇺🇸Ocoee, Florida, United States
Arthritis Center, Inc. /ID# 145647
🇺🇸Palm Harbor, Florida, United States
Rheumatology Consultants, PLLC /ID# 153731
🇺🇸Knoxville, Tennessee, United States
CCBR Brasil /ID# 150918
🇧🇷Rio de Janeiro, Brazil
Emeritus Research /ID# 142848
🇦🇺Camberwell, Victoria, Australia
Clinical Center University of Sarajevo /ID# 142865
🇧🇦Sarajevo, Bosnia and Herzegovina
Diagnostic Consultative Center /ID# 142875
🇧🇬Sofia, Bulgaria
Ctr de Inv Clinica del Sur /ID# 142888
🇨🇱Temuco, Araucania, Chile
Reg. Clinical Hosptial Concepcion /ID# 151271
🇨🇱Concepcion, Chile
Poliklinika Bonifarm /ID# 142899
🇭🇷Zagreb, Croatia
Hopital Saint Eloi /ID# 142925
🇫🇷Montpellier CEDEX 5, Herault, France
General Hospital of Athens Ippokratio /ID# 142935
🇬🇷Athens, Greece
Qualiclinic Kft. /ID# 142953
🇭🇺Budapest III, Pest, Hungary
Vilnius University Hospital /ID# 142987
🇱🇹Vilnius, Lithuania
Hospital de Jesús Nazareno /ID# 142993
🇲🇽Mexico City, Mexico
Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 142871
🇧🇷Curitiba, Parana, Brazil
CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 142867
🇧🇷São Paulo, Sao Paulo, Brazil
Soc. de Prestaciones medicas y Paramedicas Goecke /ID# 142890
🇨🇱Santiago, Chile
Klinicki bolnicki centar Split /ID# 152530
🇭🇷Split, Croatia
Hopital de la Cote de Nacre /ID# 145616
🇫🇷Caen, France
CHU Gabriel Montpied /ID# 145619
🇫🇷Clermont Ferrand, France
University General Hospital Attikon /ID# 142933
🇬🇷Athens, Attiki, Greece
CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 142951
🇭🇺Miskolc, Borsod-Abauj-Zemplen, Hungary
Hevizgyogyfurdo es Szent Andra /ID# 142949
🇭🇺Heviz, Hungary
Sheba Medical Center /ID# 145965
🇮🇱Ramat Gan, Israel
Synexus Magyarorszag Kft. /ID# 153061
🇭🇺Budapest, Hungary
Hopital de la Conception /ID# 142926
🇫🇷Marseille, France
General Hospital of Athens Laiko /ID# 142934
🇬🇷Athens, Attiki, Greece
Tel Aviv Sourasky Medical Ctr /ID# 144709
🇮🇱Tel Aviv-Yafo, Tel-Aviv, Israel
Cath Univ Seoul St Mary's Hosp /ID# 142976
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Spitalul Clinic de Recuperare /ID# 144867
🇷🇴Iasi, Romania
Orenburg State Medical Academy /ID# 143018
🇷🇺Orenburg, Russian Federation
NW State Med Univ NA Mechnikov /ID# 143022
🇷🇺St. Petersburg, Russian Federation
REUMACENTRUM s.r.o. /ID# 143041
🇸🇰Partizanske, Slovakia
Budai Irgalmasrendi Korhaz /ID# 142952
🇭🇺Budapest, Hungary
Revita Reumatologiai Rendelo /ID# 142950
🇭🇺Budapest, Hungary
Russian National Research Medi /ID# 143028
🇷🇺Moscow, Russian Federation
CHRU Lille - Hôpital Claude Huriez /ID# 151312
🇫🇷Lille CEDEX, Hauts-de-France, France
CHU de Rennes - Hospital Sud /ID# 151957
🇫🇷Rennes, France
Uniklinik Koln /ID# 145964
🇩🇪Köln, Nordrhein-Westfalen, Germany
Pest Megyei Flor Ferenc Korhaz /ID# 142954
🇭🇺Kistarcsa, Hungary
Rambam Health Care Campus /ID# 152050
🇮🇱Haifa, Israel
Inha University Hospital /ID# 150886
🇰🇷Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of
GCM Medical Group /ID# 143011
🇵🇷San Juan, Puerto Rico
Spitalul Clinic Sf. Maria /ID# 144868
🇷🇴Bucuresti, Romania
Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 143138
🇷🇺Moscow, Moskva, Russian Federation
Asan Medical Center /ID# 142974
🇰🇷Seoul, Korea, Republic of
City Clinical Hospital Botkina /ID# 145628
🇷🇺Moscow, Russian Federation
Spitalul Clinic Dr. I. Cantacuzino /ID# 143017
🇷🇴Bucharest, Bucuresti, Romania
Family Outpatient clinic#4,LLC /ID# 148319
🇷🇺Korolev, Moskva, Russian Federation
Institute for Rheumatology /ID# 143037
🇷🇸Belgrade, Beograd, Serbia
Reumex, s.r.o. /ID# 143043
🇸🇰Rimavska Sobota, Slovakia
Ulyanovsk Regional Clin Hosp /ID# 143030
🇷🇺Ulyanovsk, Russian Federation
Synexus Helderberg Clinical Tr /ID# 148322
🇿🇦Cape Town, Western Cape, South Africa
Regional Clinical Hospital /ID# 152025
🇺🇦Ivano-frankivsk, Ukraine
Special Hospital for Rheuma /ID# 143034
🇷🇸Novi Sad, Vojvodina, Serbia
Chung Shan Medical University /ID# 143060
🇨🇳Taichung City, Taiwan
Linkou Chang Gung Memorial Ho /ID# 143057
🇨🇳Taoyuan City, Taiwan
Rheum Assoc of Central FL /ID# 145632
🇺🇸Orlando, Florida, United States
Omega Research Consultants /ID# 145635
🇺🇸Orlando, Florida, United States
HMD Research LLC /ID# 163292
🇺🇸Orlando, Florida, United States
SW Rheumatology Res. LLC /ID# 143126
🇺🇸Mesquite, Texas, United States
Advanced Clinical Research /ID# 153090
🇺🇸Meridian, Idaho, United States
Arthritis and Rheum Clin N. CO /ID# 156094
🇺🇸Fort Collins, Colorado, United States
Arthritis Center of North GA /ID# 155258
🇺🇸Gainesville, Georgia, United States
Jakaranda Hosp, Emmed Research /ID# 145968
🇿🇦Pretoria, Gauteng, South Africa
Moscow State Univ Med and Dent /ID# 145623
🇷🇺Moscow, Russian Federation
China Medical University Hosp /ID# 143058
🇨🇳Taichung City, Taichung, Taiwan
St. Augustine's Hospital /ID# 143047
🇿🇦Durban, Kwazulu-Natal, South Africa
Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 143071
🇺🇦Vinnytsia, Vinnytska Oblast, Ukraine
Queen Mary Hospital /ID# 142938
🇭🇰Hong Kong, Hong Kong
Tuen Mun Hospital /ID# 142939
🇭🇰Tuen Mun, Hong Kong